Heparin (Mucous) Leo Laboratories

Heparin (Mucous) from Leo Laboratories is a pharmaceutical preparation containing heparin sodium as the active ingredient. It is supplied in an injectable form for intravenous or subcutaneous administration, though specific strength and dosage form are not disclosed. The product is marketed in the European Union and is classified as a prescription‑only anticoagulant. Heparin works by enhancing antithrombin III activity, which reduces clotting factor function and helps prevent thrombus formation.

Heparin (Mucous) Leo Laboratories is indicated for several clinical situations where inhibition of clot formation is required.

- Prevention and treatment of venous thromboembolism, including deep‑vein thrombosis and pulmonary embolism. - Prophylaxis of clot formation during cardiac surgery, cardiopulmonary bypass, and hemodialysis procedures. - Management of acute coronary syndromes such as unstable angina and non‑ST‑segment elevation myocardial infarction. - Use as an anticoagulant bridge when transitioning between oral anticoagulants. - Adjunctive therapy in patients with hypercoagulable states pending definitive treatment.

Adverse reactions to Heparin (Mucous) Leo Laboratories vary in frequency and severity.

Common: - Minor bleeding at the injection site or mild epistaxis. - Small hematoma formation. - Transient elevation of liver enzymes. - Nausea or mild headache. - Transient hypotension following rapid intravenous infusion.

Serious: - Major hemorrhage, including internal bleeding. - Heparin‑induced thrombocytopenia (HIT) with risk of thrombosis. - Spontaneous spinal or epidural hematoma. - Allergic reactions such as urticaria, angioedema, or anaphylaxis.

Before initiating therapy with Heparin (Mucous) Leo Laboratories, clinicians should consider several precautionary measures to minimize risk.

- Assess baseline platelet count and monitor for sudden declines. - Evaluate renal and hepatic function, especially in patients with impairment. - Use caution in individuals with a history of bleeding disorders or recent surgery. - Avoid use in patients with known hypersensitivity to heparin or pork‑derived products. - Adjust dose or discontinue if signs of heparin‑induced thrombocytopenia appear. - Consider pregnancy status, as safety data are limited.

Heparin (Mucous) Leo Laboratories may interact with other medications, influencing anticoagulant effect or bleeding risk.

Avoid: - Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) without careful monitoring. - Thrombolytic agents such as alteplase or streptokinase. - High‑dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs). - Antiplatelet agents like clopidogrel when combined may increase bleeding.

Use with caution: - Glycoprotein IIb/IIIa inhibitors (e.g., abciximab). - Certain antibiotics (e.g., vancomycin) that may potentiate anticoagulation. - Hormonal therapies (e.g., estrogen‑containing contraceptives) that affect clotting risk.